Control of pain initiation by endogenous cannabinoids

A. Calignano, G. L A Ranna, Andrea Giuffrida, D. Piomelli

Research output: Contribution to journalArticle

Abstract

The potent analgesic effects of cannabis-like drugs and the presence of CBl-type receptors in pain-processing areas of the brain and spinal cord indicated that endogenous cannabinoids such as anandamide may contribute to the control of pain transmission within the central nervous system (CNS). Here we show that anandamide attenuates the pain behavior produced by chemical damage to cutaneous tissue by interacting with CBl-like cannabinoid receptors located outside the CNS. Palmitylethanolamide (PEA), which is released together with anandamide from a common phospholipid precursor, exerts a similar effect by activating peripheral CB2-like receptors. When administered together, the two compounds act synergistically, reducing the pain responses 100-fold more potently than does each compound alone. Gas-chromatography/mass-spectrometry measurements indicate that the levels of anandamide and PEA in the skin are enough to cause a tonic activation of local cannabinoid receptors. In agreement with this possibility, the CB1 antagonist SR121716A and the CB2 antagonist SR144528 prolong and enhance pain behavior produced by tissue damage. These results indicate that peripheral CBl-like and CB2-like receptors participate in the intrinsic control of pain initiation and that locally generated anandamide and PEA may mediate this effect.

Original languageEnglish (US)
Pages (from-to)132
Number of pages1
JournalProceedings of the Western Pharmacology Society
Volume42
StatePublished - 1999
Externally publishedYes

Fingerprint

Cannabinoids
Pain
Cannabinoid Receptor CB2
Cannabinoid Receptors
Central Nervous System
Skin
Nociceptors
Cannabis
Gas Chromatography-Mass Spectrometry
Analgesics
Phospholipids
Spinal Cord
anandamide
Brain
Pharmaceutical Preparations
palmidrol

ASJC Scopus subject areas

  • Pharmacology

Cite this

Control of pain initiation by endogenous cannabinoids. / Calignano, A.; Ranna, G. L A; Giuffrida, Andrea; Piomelli, D.

In: Proceedings of the Western Pharmacology Society, Vol. 42, 1999, p. 132.

Research output: Contribution to journalArticle

@article{9d4445b50aff4c3bba9945338ae5f7d0,
title = "Control of pain initiation by endogenous cannabinoids",
abstract = "The potent analgesic effects of cannabis-like drugs and the presence of CBl-type receptors in pain-processing areas of the brain and spinal cord indicated that endogenous cannabinoids such as anandamide may contribute to the control of pain transmission within the central nervous system (CNS). Here we show that anandamide attenuates the pain behavior produced by chemical damage to cutaneous tissue by interacting with CBl-like cannabinoid receptors located outside the CNS. Palmitylethanolamide (PEA), which is released together with anandamide from a common phospholipid precursor, exerts a similar effect by activating peripheral CB2-like receptors. When administered together, the two compounds act synergistically, reducing the pain responses 100-fold more potently than does each compound alone. Gas-chromatography/mass-spectrometry measurements indicate that the levels of anandamide and PEA in the skin are enough to cause a tonic activation of local cannabinoid receptors. In agreement with this possibility, the CB1 antagonist SR121716A and the CB2 antagonist SR144528 prolong and enhance pain behavior produced by tissue damage. These results indicate that peripheral CBl-like and CB2-like receptors participate in the intrinsic control of pain initiation and that locally generated anandamide and PEA may mediate this effect.",
author = "A. Calignano and Ranna, {G. L A} and Andrea Giuffrida and D. Piomelli",
year = "1999",
language = "English (US)",
volume = "42",
pages = "132",
journal = "Proceedings of the Western Pharmacology Society",
issn = "0083-8969",
publisher = "Western Pharmacology Society",

}

TY - JOUR

T1 - Control of pain initiation by endogenous cannabinoids

AU - Calignano, A.

AU - Ranna, G. L A

AU - Giuffrida, Andrea

AU - Piomelli, D.

PY - 1999

Y1 - 1999

N2 - The potent analgesic effects of cannabis-like drugs and the presence of CBl-type receptors in pain-processing areas of the brain and spinal cord indicated that endogenous cannabinoids such as anandamide may contribute to the control of pain transmission within the central nervous system (CNS). Here we show that anandamide attenuates the pain behavior produced by chemical damage to cutaneous tissue by interacting with CBl-like cannabinoid receptors located outside the CNS. Palmitylethanolamide (PEA), which is released together with anandamide from a common phospholipid precursor, exerts a similar effect by activating peripheral CB2-like receptors. When administered together, the two compounds act synergistically, reducing the pain responses 100-fold more potently than does each compound alone. Gas-chromatography/mass-spectrometry measurements indicate that the levels of anandamide and PEA in the skin are enough to cause a tonic activation of local cannabinoid receptors. In agreement with this possibility, the CB1 antagonist SR121716A and the CB2 antagonist SR144528 prolong and enhance pain behavior produced by tissue damage. These results indicate that peripheral CBl-like and CB2-like receptors participate in the intrinsic control of pain initiation and that locally generated anandamide and PEA may mediate this effect.

AB - The potent analgesic effects of cannabis-like drugs and the presence of CBl-type receptors in pain-processing areas of the brain and spinal cord indicated that endogenous cannabinoids such as anandamide may contribute to the control of pain transmission within the central nervous system (CNS). Here we show that anandamide attenuates the pain behavior produced by chemical damage to cutaneous tissue by interacting with CBl-like cannabinoid receptors located outside the CNS. Palmitylethanolamide (PEA), which is released together with anandamide from a common phospholipid precursor, exerts a similar effect by activating peripheral CB2-like receptors. When administered together, the two compounds act synergistically, reducing the pain responses 100-fold more potently than does each compound alone. Gas-chromatography/mass-spectrometry measurements indicate that the levels of anandamide and PEA in the skin are enough to cause a tonic activation of local cannabinoid receptors. In agreement with this possibility, the CB1 antagonist SR121716A and the CB2 antagonist SR144528 prolong and enhance pain behavior produced by tissue damage. These results indicate that peripheral CBl-like and CB2-like receptors participate in the intrinsic control of pain initiation and that locally generated anandamide and PEA may mediate this effect.

UR - http://www.scopus.com/inward/record.url?scp=33748126240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748126240&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748126240

VL - 42

SP - 132

JO - Proceedings of the Western Pharmacology Society

JF - Proceedings of the Western Pharmacology Society

SN - 0083-8969

ER -